Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma Statistics

Total Valuation

ABUS has a market cap or net worth of $649.01 million. The enterprise value is $531.64 million.

Market Cap	649.01M
Enterprise Value	531.64M

Important Dates

The last earnings date was Wednesday, November 6, 2024, before market open.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

ABUS has 189.49 million shares outstanding. The number of shares has increased by 10.83% in one year.

Current Share Class	189.49M
Shares Outstanding	189.49M
Shares Change (YoY)	+10.83%
Shares Change (QoQ)	+0.51%
Owned by Insiders (%)	0.82%
Owned by Institutions (%)	47.30%
Float	136.22M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	92.55
Forward PS	110.35
PB Ratio	6.13
P/TBV Ratio	6.04
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	78.86
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 7.02, with a Debt / Equity ratio of 0.06.

Current Ratio	7.02
Quick Ratio	6.85
Debt / Equity	0.06
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-520.17

Financial Efficiency

Return on equity (ROE) is -67.81% and return on invested capital (ROIC) is -40.40%.

Return on Equity (ROE)	-67.81%
Return on Assets (ROA)	-32.83%
Return on Capital (ROIC)	-40.40%
Revenue Per Employee	$92,356
Profits Per Employee	-$1.05M
Employee Count	73
Asset Turnover	0.05
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +66.75% in the last 52 weeks. The beta is 1.78, so ABUS's price volatility has been higher than the market average.

Beta (5Y)	1.78
52-Week Price Change	+66.75%
50-Day Moving Average	3.80
200-Day Moving Average	3.40
Relative Strength Index (RSI)	31.88
Average Volume (20 Days)	915,655

Short Selling Information

The latest short interest is 6.06 million, so 3.20% of the outstanding shares have been sold short.

Short Interest	6.06M
Short Previous Month	6.54M
Short % of Shares Out	3.20%
Short % of Float	4.45%
Short Ratio (days to cover)	6.34

Income Statement

In the last 12 months, ABUS had revenue of $6.74 million and -$76.70 million in losses. Loss per share was -$0.43.

Revenue	6.74M
Gross Profit	-56.05M
Operating Income	-78.55M
Pretax Income	-77.09M
Net Income	-76.70M
EBITDA	-77.14M
EBIT	-78.55M
Loss Per Share	-$0.43

Balance Sheet

The company has $127.79 million in cash and $6.76 million in debt, giving a net cash position of $124.00 million or $0.65 per share.

Cash & Cash Equivalents	127.79M
Total Debt	6.76M
Net Cash	124.00M
Net Cash Per Share	$0.65
Equity (Book Value)	106.89M
Book Value Per Share	0.56
Working Capital	113.85M

Cash Flow

In the last 12 months, operating cash flow was -$71.83 million and capital expenditures -$96,000, giving a free cash flow of -$71.92 million.

Operating Cash Flow	-71.83M
Capital Expenditures	-96,000
Free Cash Flow	-71.92M
FCF Per Share	-$0.38

Margins

Gross Margin	n/a
Operating Margin	-1,165.03%
Pretax Margin	-1,137.64%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-725.41%

Dividends & Yields

ABUS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.83%
Shareholder Yield	-10.83%
Earnings Yield	-11.89%
FCF Yield	-11.15%

Analyst Forecast

The average price target for ABUS is $5.50, which is 60.58% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$5.50
Price Target Difference	60.58%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	46.29%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ABUS has an Altman Z-Score of -4.92 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-4.92
Piotroski F-Score	3